Sage Therapeutics Inc (SG7.BE)
| Previous close | 9.78 |
| Open | 9.84 |
| Bid | 9.97 x N/A |
| Ask | 10.24 x N/A |
| Day's range | 9.48 - 10.10 |
| 52-week range | 9.48 - 55.00 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Investing.com
Baird predicts steady growth for SAGE Therapeutics at $15 target
Investing.com - Baird Equity Research has initiated coverage of SAGE Therapeutics Inc (NASDAQ:SAGE), assigning it a neutral rating with a price target of $15.
- Insider Monkey
15 Most Depressed States in the US
In this article, we will be taking a look at the 15 most depressed states in the US. If you are not interested in learning about the global and regional trends in the depression treatment market, head straight to the 5 Most Depressed States in the US. Global and Regional Trends in the Depression Treatment […]
- Insider Monkey
Sage Therapeutics, Inc. (NASDAQ:SAGE) Q1 2024 Earnings Call Transcript
Sage Therapeutics, Inc. (NASDAQ:SAGE) Q1 2024 Earnings Call Transcript April 25, 2024 Sage Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-1.8 EPS, expectations were $-1.63. Sage Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, […]
